Daniel E. Furst
YOU?
Author Swipe
View article: Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee Open
Introduction: Digital ulcers are an important disease manifestation of systemic sclerosis and are associated with significant morbidity. As such, there is an urgent need for the development of evidence-based recommendations to guide clinic…
View article: Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’
Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) ‘Ad hoc committee’ Open
Introduction: Digital ulcers (DUs) stand out as one of the most prevalent and clinically meaningful manifestations of systemic sclerosis (SSc) and are associated with significant morbidity. While systemic (pharmacological) therapy is curre…
View article: Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study Open
Objectives To determine the efficacy, safety and pharmacodynamics of belumosudil in patients with diffuse cutaneous systemic sclerosis (dcSSc) treated with background immunosuppressive therapies. Methods Eligible patients were randomised 1…
View article: Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis Open
Objectives The RESOLVE‐1 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc) allowed background immunosuppressive therapy (IST) at the discretion of individual investigators, and no significant differences were observed betw…
View article: A Scoping Literature Review of Lung HRCT in Connective Tissue Disease: Descriptions and Prediction of Mortality
A Scoping Literature Review of Lung HRCT in Connective Tissue Disease: Descriptions and Prediction of Mortality Open
Background and Objectives: This scoping literature review is intended to describe the characteristic HRCT lung findings related to interstitial lung disease (ILD) which occur in: dermatomyositis/polymyositis (DM/PM), rheumatoid arthritis (…
View article: What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives
What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives Open
Objective This study aimed to expand the understanding of the patient with psoriatic arthritis (PsA) experience and to compare/contrast patient and clinician prioritization of PsA dimensions. Methods We conducted four patients with PsA foc…
View article: Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial Open
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ sele…
View article: Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study
Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study Open
CRD42020171124.
View article: The Impact of CMV-Prophylaxis with Letermovir on Immune Reconstitution after Allogeneic Stem Cell Transplantation: Single-Center Analysis of 363 Transplanted Patients
The Impact of CMV-Prophylaxis with Letermovir on Immune Reconstitution after Allogeneic Stem Cell Transplantation: Single-Center Analysis of 363 Transplanted Patients Open
Introduction. Letermovir (LTV) showed to reduce the incidence of Cytomegalovirus (CMV) reactivations in CMV-seropositive patients after allogeneic stem cell transplantation (allo-SCT). CMV reactivations are known to stimulate polyfunctiona…
View article: Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases
Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases Open
This study identifies dysregulated gene expression (KRT and MMP8) associated with neutrophil function and increased megakaryocytes in SSc, highlighting common patterns across autoimmune diseases. These findings offer new insights into the …
View article: The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases
The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases Open
The gut microbiota is a complex ecosystem of microorganisms residing in the human gastrointestinal tract, playing a crucial role in various biological processes and overall health maintenance. Dysbiosis, an imbalance in the composition and…
View article: Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis Open
Background Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in s…
View article: Oral health in systemic sclerosis: A scoping review
Oral health in systemic sclerosis: A scoping review Open
Background: Limited research on oral health in systematic sclerosis poses a significant challenge for people with systematic sclerosis and health care professionals. We conducted a scoping review to map existing research on oral health–rel…
View article: Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines
Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines Open
This predictive model demonstrates robust capability to assess ILD risk in IIM patients, particularly when augmented with serum KL-6 level or/and LUS B-line number.
View article: Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma Open
Our data confirm that the treatment with ide-cel is feasible for patients with prior allo-HSCT. Furthermore, allo-HSCT did not influence cellular composition of lymphocyte collections, clinical outcome or in vivo expansion of ide-cel.
View article: What comes before scleroderma?
What comes before scleroderma? Open
While the classification criteria for systemic sclerosis (SSc) have been carefully delineated, the definition of what comes before meeting classification criteria is not so well understood. In some ways, it is similar to “pre-rheumatoid ar…
View article: Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures
Myeloablation Followed by Hematopoietic Stem Cell Transplantation and Long‐Term Normalization of Systemic Sclerosis Molecular Signatures Open
Objective In the randomized Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial, myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to the normalization of systemic sclerosis (SSc) peripheral blood cel…
View article: The Rising Challenge of Poor Health Literacy of Patients with Systemic Sclerosis: Preliminary Data Identify Important Unmet Needs in an Italian Cohort
The Rising Challenge of Poor Health Literacy of Patients with Systemic Sclerosis: Preliminary Data Identify Important Unmet Needs in an Italian Cohort Open
Rationale and aim: Health literacy (HL) is pivotal for the successful self-management of chronic diseases. Little HL information is currently available in SSc patients; therefore, the present study aims at evaluating the HL levels in an It…
View article: A Prospective, Controlled, Pilot Study of Personalised Add-on Ayurveda Treatment in High-Risk Type II Diabetes COVID-19 Patients
A Prospective, Controlled, Pilot Study of Personalised Add-on Ayurveda Treatment in High-Risk Type II Diabetes COVID-19 Patients Open
In hospitalized mild to moderate COVID-19 Patients with pre-existing Type 2 diabetes, we evaluated the efficacy of add-on customized Ayurveda intervention as compared to Standard of Care (SOC) in ameliorating symptoms, ICU admission and Ve…
View article: Economic and Health Care Resource Use Burden of Systemic Sclerosis
Economic and Health Care Resource Use Burden of Systemic Sclerosis Open
Objective To describe the health care resource use (HCRU) and costs of patients with systemic sclerosis (SSc) prior to and after diagnosis. Methods This retrospective study used a claims data set (Merative MarketScan; 2015‐2019). Eligible …
View article: A Prospective, controlled, pilot study of personalized add-on Ayurveda treatment in high-risk Type II Diabetes COVID-19 patients
A Prospective, controlled, pilot study of personalized add-on Ayurveda treatment in high-risk Type II Diabetes COVID-19 patients Open
Objective In hospitalized mild to moderate COVID-19 Patients with Type 2 diabetes, we evaluated the efficacy of add-on customized Ayurveda intervention as compared to Standard of Care (SOC) in ameliorating symptoms, ICU admission and Venti…
View article: Does the Impact of <scp>COVID</scp>‐19 on Patients With Systemic Sclerosis Change Over Time?
Does the Impact of <span>COVID</span>‐19 on Patients With Systemic Sclerosis Change Over Time? Open
Objective The outcome of patients with COVID‐19 improved over the pandemic, including patients with systemic rheumatic diseases. However, data on patients with systemic sclerosis (SSc) are lacking. This study aimed to assess the outcome of…
View article: Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review Open
Objective To evaluate the evidence concerning systemic pharmacological treatments for SSc digital ulcers (DUs) to inform the development of evidence-based treatment guidelines. Methods A systematic literature review of seven databases was …